OTLK Valuation

Outlook Therapeutics Inc

Add to Watchlist

Advanced Chart

1.240

+0.040(+3.330%)

Overview
Forecast
Valuation

OTLK Relative Valuation

OTLK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OTLK is overvalued; if below, it's undervalued.

Historical Valuation

Outlook Therapeutics Inc (OTLK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.43 is considered Undervalued compared with the five-year average of 319.45. The fair price of Outlook Therapeutics Inc (OTLK) is between 4.95 to 34.42 according to relative valuation methord. Compared to the current price of 1.24 USD , Outlook Therapeutics Inc is Undervalued By 74.96%.

Relative Value

Fair Zone

4.95-34.42

Current Price：1.24

74.96%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-0.59

P/B

Median3y

2.46

Median5y

9.81

-179.67

FCF Yield

Median3y

-43.63

Median5y

-33.82

Competitors Valuation Multiple

The average P/S ratio for OTLK's competitors is 1.69, providing a benchmark for relative valuation. Outlook Therapeutics Inc Corp (OTLK) exhibits a P/S ratio of 2.43, which is 43.76% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

OTLK.O

Outlook Therapeutics Inc

2.43

Average P/S: 1.69

40.45M